Neuland Laboratories Ltd Financials
Company Logo

Neuland Laboratories Ltd Financial Statement

Neuland Laboratories Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue315.18
Operating Expense249.50
Net Profit31.96
Net Profit Margin10.14
Earning Per Share24.91
EBIDTA61.30
Effective Tax Rate18.59
Invest in Neuland Laboratories Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Neuland Laboratories Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual1,558.58
Operating Expenses Annual1,096.66
Operating Profit Annual474.47
Interest Annual14.00
Depreciation58.64
Net Profit Annual299.60
Tax Annual101.17

Neuland Laboratories Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning44.96
Cash Flow from Operations260.06
Cash Flow from Investing-149.67
Cash Flow from Financing-69.28
Cash Flow at the End86.07

Neuland Laboratories Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)30.44
PBIT Margin (%)26.61
PBT Margin (%)24.71
Net PROFIT Margin (%)19.22
Return On Networth / Equity (%)26.48
Return On Networth /Employed (%)33.13
Return On Assets (%)23.84
Total Debt / Equity (X)0.10
Asset Turnover Ratio (%)1.24

Neuland Laboratories Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual804.63
Total Current Assets Annual919.47
Non Current Assets Annual911.46
Total Shareholders Funds Annual1,276.54
Total Assets Annual1,830.93

Neuland Laboratories Ltd Earning Calls

EPS (INR)

Expected

25.46

Reported

25.60

Surprise

0.55%

Jun 2024

EPS beaten by 0.55%

Mar 2024

EPS beaten by 0.54%

Dec 2023

EPS beaten by 0.55%

Get Your FAQs Right

As of Nov 23, 2024, Neuland Laboratories Ltd has a market capitalization of 8,058.84 Cr. Value Research classifies it as a Mid-Cap company.
Yes, Neuland Laboratories Ltd is debt-free with a debt-to-equity ratio of 0.07.
In FY 2023 , Neuland Laboratories Ltd recorded a total revenue of approximately 1,558.58 Cr marking a significant milestone in the company's financial performance.
Neuland Laboratories Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.9% and 0.2% annually, respectively..
Neuland Laboratories Ltd's current PE ratio is 26.90.
Neuland Laboratories Ltd's ROCE averaged 19.8% from the FY ending March 2022 to 2024, with a median of 20.4%. It peaked at 30.2% in March 2024, reflecting strong capital efficiency over the period..
Neuland Laboratories Ltd's latest EBIT is Rs. 414.77 Cr, surpassing the average EBIT of Rs. 246.09 Cr over the 5 years..